Clinical Trials
10 trialsNCT03698994 2026-05-27
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05627245 2026-05-13
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03506373 2026-05-05
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
Mayo Clinic
Phase 2 Terminated
NCT03537690 2026-04-29
FID-007 in Treating Participants With Advanced Solid Tumors
University of Southern California
Phase 1 Active not recruiting
NCT03479268 2026-04-27
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT01165333 2026-03-16
CILENT
Centre Oscar Lambret
Phase 1 Completed
NCT03582124 2026-02-10
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford University
Phase 1/2 Recruiting
NCT03225664 2026-01-16
Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT03259503 2025-11-10
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03300557 2025-08-29
Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed